Free Trial
Navann Ty

Navann Ty Analyst Performance

Senior Research Analyst at BNP Paribas Exane

Navann Ty is a stock analyst at BNP Paribas Exane focused in the medical sector, covering 3 publicly traded companies. Over the past year, Navann Ty has issued 3 stock ratings, including and hold recommendations. While full access to Navann Ty's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Navann Ty's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
3 Last 0 Years
Buy Recommendations
0.00% 0 Buy Ratings
Companies Covered
3 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy0.0%0 ratings
Hold100.0%3 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Hold recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
66.7% of companies on NASDAQ
2 companies
NYSE
33.3% of companies on NYSE
1 company

Navann Ty, an analyst at BNP Paribas Exane, currently covers 3 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
66.7%
Manufacturing
1 company
33.3%

Navann Ty of BNP Paribas Exane specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MEDICAL SERVICES
2 companies
66.7%
SURGICAL, MEDICAL, AND DENTAL INSTRUMENTS AND SUPPLIES
1 company
33.3%

Navann Ty's Ratings History at BNP Paribas Exane

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Medline stock logo
MDLN
Medline
5/14/2026Lower Price Target$39.00$40.00Neutral
Organon & Co. stock logo
OGN
Organon & Co.
4/29/2026Reiterated Rating$13.33$14.00Neutral
Natera, Inc. stock logo
NTRA
Natera
10/27/2025Upgrade$191.98$172.00Hold